109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
重新审视住院新冠肺炎患者使用 Janus 激酶抑制剂的情况：巴瑞替尼的优越性证据及缺乏类效应
Authors Gu L, Lin J , Yue J, Liu Z, Huang JA
Received 19 July 2025
Accepted for publication 30 September 2025
Published 11 October 2025 Volume 2025:18 Pages 14171—14173
DOI https://doi.org/10.2147/JIR.S554898
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Tara Strutt
Lei Gu,1,* Jing Lin,2,* Jian Yue,3,* Zeyi Liu,1 Jian-an Huang1
1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 3The People’s Hospital of Gaozhou, Gaozhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jian-an Huang, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Email huang_jian_an@163.com Zeyi Liu, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Email liuzeyisuda@163.com
Abstract: Janus kinase (JAK) inhibitors, developed for autoimmune diseases, have been repurposed as potential therapies for severe COVID-19. Growing evidence indicates that their clinical utility is heterogeneous and cannot be generalized as a class effect. In this Perspective, we focus on the clinical evidence base for JAK inhibitors in COVID-19 and emphasize baricitinib as the the only agent with consistent mortality benefit and highlights the need for agent-specific recommendations and individualized treatment strategies.
Keywords: janus kinase inhibitors, baricitinib, tofacitinib, ruxolitinib, COVID-19, immunomodulation
1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 3The People’s Hospital of Gaozhou, Gaozhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jian-an Huang, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Email huang_jian_an@163.com Zeyi Liu, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China, Email liuzeyisuda@163.com
Abstract: Janus kinase (JAK) inhibitors, developed for autoimmune diseases, have been repurposed as potential therapies for severe COVID-19. Growing evidence indicates that their clinical utility is heterogeneous and cannot be generalized as a class effect. In this Perspective, we focus on the clinical evidence base for JAK inhibitors in COVID-19 and emphasize baricitinib as the the only agent with consistent mortality benefit and highlights the need for agent-specific recommendations and individualized treatment strategies.
Keywords: janus kinase inhibitors, baricitinib, tofacitinib, ruxolitinib, COVID-19, immunomodulation